A detailed history of O'Rourke & Company, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, O'Rourke & Company, Inc holds 2,916 shares of ABBV stock, worth $524,880. This represents 0.29% of its overall portfolio holdings.

Number of Shares
2,916
Previous 2,913 0.1%
Holding current value
$524,880
Previous $500,000 15.0%
% of portfolio
0.29%
Previous 0.28%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$163.84 - $199.33 $491 - $597
3 Added 0.1%
2,916 $575,000
Q2 2024

Jul 18, 2024

BUY
$154.79 - $180.76 $464 - $542
3 Added 0.1%
2,913 $500,000
Q1 2024

Apr 18, 2024

BUY
$159.82 - $182.1 $479 - $546
3 Added 0.1%
2,910 $530,000
Q4 2023

Jan 24, 2024

BUY
$137.6 - $154.97 $963 - $1,084
7 Added 0.24%
2,907 $451,000
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $935 - $1,082
7 Added 0.24%
2,900 $432,000
Q2 2023

Jul 25, 2023

SELL
$132.51 - $164.9 $3,577 - $4,452
-27 Reduced 0.92%
2,893 $390,000
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $867 - $999
6 Added 0.21%
2,920 $465,000
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $33,332 - $39,974
241 Added 9.02%
2,914 $471,000
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $2,684 - $3,078
-20 Reduced 0.74%
2,673 $359,000
Q2 2022

Aug 12, 2022

SELL
$137.62 - $174.96 $15,138 - $19,245
-110 Reduced 3.92%
2,693 $412,000
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $19,137 - $23,743
145 Added 5.46%
2,803 $454,000
Q4 2021

Feb 16, 2022

BUY
$107.43 - $135.93 $285,548 - $361,301
2,658 New
2,658 $360,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track O'Rourke & Company, Inc Portfolio

Follow O'Rourke & Company, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Rourke & Company, Inc, based on Form 13F filings with the SEC.

News

Stay updated on O'Rourke & Company, Inc with notifications on news.